Why the study?
Does monitoring of prothrombin fragment F1+2 predict recurrent venous thromboembolism in patients with a history of venous thrombosis?
Does monitoring of prothrombin fragment F1+2 predict recurrent venous thromboembolism in patients with a history of venous thrombosis?
Monitoring of prothrombin fragment F1+2 is not suitable for identifying individuals at risk of recurrent venous thrombosis after discontinuation of oral anticoagulants.
Answers are grounded in this paper and cite their sources.
F1+2 monitoring does not predict recurrent VTE after OAC stop; does not support its use and leaves open alternative biomarker studies.
It would be important to estimate in advance the risk of recurrent thrombosis. Deficiencies of antithrombin, protein C or protein S, or resistance to activated protein C are associated with a biochemically detectable prethrombotic state. It is thus far unknown whether in patients with a history of thromboembolism but without a defined clotting abnormality a heightened coagulation activation is detectable. We investigated the value of prothrombin fragment F1+2 (F1+2) as a predictor of recurrent venous thromboembolism. Furthermore, we compared the F1+2 levels of thrombosis patients without a defined clotting defect to those of Factor V Leiden patients with a history of venous thrombosis and to those of healthy controls. 180 patients without a defined clotting abnormality and 73 patients with Factor V Leiden were prospectively followed after discontinuation of oral anticoagulants for venous thrombosis and F1+2 was measured at regular intervals. Recurrent venous thromboembolism occurred in 23 (9%) of the 253 patients. Before or at several time points after oral anticoagulants, no significant difference in F1+2 levels was found in patients with and without recurrent thrombosis. F1+2 levels at 3 weeks and prior to recurrence were not significantly different in both patient groups. Over a one-year observation period, F1+2 levels of both patients with and without Factor V Leiden were higher than those of the controls. No difference in F1+2 was seen between patients with and without Factor V Leiden. We conclude that monitoring of F1+2 is not suitable for identification of individuals at risk of recurrent venous thrombosis. Permanent hemostatic system activation is detectable both in patients with a defined abnormality of the clotting system and in patients in whom a particular defect has not (yet) been identified.
No takes yet. Share an insight, caveat, or question.
Kyrle et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: